Dong-A Socio Holdings
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dong-A Socio Holdings
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.
A Scrip roundup of 2021 earnings for major Korean pharma firms shows top performers included Hanmi Pharma, GC Pharma and SK Group affiliates, which were boosted by new license deals, strong overseas sales and high-margin vaccines and other products.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- OTC, Consumer
In Vitro Diagnostics
- Chemistry, Immunoassay
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Dong-A Pharmaceutical Co., Ltd (Dong-A Pharm)
- Dong-A Science Technology Co., Ltd (Dong-A ST)
- Dong-A Socio Group
- JCOM Co. Ltd.
- Mezzion Co. Ltd.